Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04457076
Other study ID # CMDOC-0062
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date January 1, 2025
Est. completion date January 1, 2031

Study information

Verified date February 2024
Source Sebela Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the contraceptive efficacy (prevention of pregnancy) of LevoCept


Description:

Study Design: Prospective, multi-center, single-arm, open-label, Phase 3 clinical study to 3 years with extension up to 5 years Number of Subjects: Approximately 1,525 subjects will be enrolled into the study Study Population: Post-menarcheal, pre-menopausal women up to age 45 years, who are at risk for pregnancy and who desire a long-term intrauterine contraceptive for birth control will be eligible for this study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1525
Est. completion date January 1, 2031
Est. primary completion date January 1, 2029
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A to 45 Years
Eligibility Inclusion Criteria: 1. Post-menarcheal, pre-menopausal females up to 45 years of age at the time of informed consent/assent and in good general health; 2. History of regular menstrual cycles defined as occurring every 21-35 days when not using hormones or prior to recent pregnancy or spontaneous or induced abortion; 3. Sexually active with a male partner who has not had a vasectomy nor other known fertility problems; 4. Reasonably expect to have coitus at least once monthly during the study period; 5. In a mutually monogamous relationship of at least 3 months duration at time of consent; 6. Seeking to avoid pregnancy for the duration of the study; 7. Willing to use the study drug as the sole form of contraception; 8. Willing to accept a risk of pregnancy; 9. Subjects must be in compliance with cervical cancer screening guidelines per the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines without evidence of disease. Subjects who are age 21 to 24 y/o, at time of informed consent, must have a normal Papanicolaou test (Pap), atypical squamous cells of undetermined significance (ASC-US), or low-grade squamous intraepithelial lesion (LSIL). Subjects who are 25 or older at the time of informed consent must have a normal Pap test or an ASC-US result with a negative high-risk human papilloma virus (HPV) test result within the appropriate screen timeframe per ASCCP guidelines, and prior to the study IUD insertion. Alternatively, the subject must have had a colposcopy performed within the appropriate screen timeframe, and prior to the study IUD insertion that showed no evidence of dysplasia requiring treatment per ASCCP guidelines, or treatment was performed and follow-up at least 6 months after the treatment showed no evidence of disease by clinical evaluation; 10. Able and willing to comply with all study tests, procedures, assessment tools (including e-diary) and follow-up; 11. Able and willing to provide and document informed consent and Authorization for Release of Protected Health Information (PHI). Unemancipated subjects under 18 years old must provide assent and have written parental/legal guardian consent documented on the consent form consistent with local legal requirements; 12. Plan to reside within a reasonable travel distance of a research site for the duration of the study. 13. Subject agrees not to intentionally self-remove LevoCept Exclusion Criteria: 1. Known or suspected pregnancy; or at risk for pregnancy from unprotected intercourse earlier in current cycle; 2. Has had any procedure for or causing sterility (e.g. tubal ligation procedure); 3. Subject who anticipates separation from her partner for more than a 6-month period during use of LevoCept; 4. A previously inserted IUD/IUS that has not been removed by the time the study IUS is placed; 5. History of previous IUD/IUS complications, such as perforation, expulsion, or pregnancy with IUD/IUS in place; 6. Pain with current IUD/IUS; 7. Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months and has not had 2 normal menstrual cycles since the last injection; 8. Subject is <4 weeks post-pregnancy (postpartum, spontaneous or induced abortion) 9. Planned use of any non-contraceptive estrogen, progesterone or testosterone any time during the 60 months of study participation; 10. Exclusively breastfeeding before return of menses; lactating women will be excluded unless they have had 2 normal menstrual periods prior to enrollment; 11. Unexplained abnormal uterine bleeding (suspicious for a serious condition), including bleeding 4 weeks post-septic abortion or puerperal sepsis; 12. Severely heavy or painful menstrual bleeding; 13. Suspected or known cervical, uterine or ovarian cancer, or unresolved clinically significant abnormal Pap test requiring evaluation or treatment; 14. Any history of gestational trophoblastic disease with or without detectable elevated ß-human chorionic gonadotropin (ß-hCG) levels, or related malignant disease; 15. Any congenital or acquired uterine anomaly that may complicate study drug placement, such as: - Submucosal uterine leiomyoma - Asherman's syndromes - Pedunculated polyps - Bicornuate uterus - Didelphus or uterine septa 16. Any distortions of the uterine cavity (e.g. fibroids), that, in the opinion of the investigator, are likely to cause issues during insertion, retention or removal of the IUS; 17. Known anatomical abnormalities of the cervix such as severe cervical stenosis, prior trachelectomy or extensive conization that, in the opinion of the investigator would prevent cervical dilation and study drug placement; 18. Untreated or unresolved acute cervicitis or vaginitis; 19. Known or suspected breast cancer or other progestin-sensitive cancer now or in the past; 20. Known acute liver disease or liver tumor; 21. Subjects who have an established immunodeficiency; 22. Known or suspected human immunodeficiency virus (HIV) infection or clinical AIDS; 23. At high risk for sexually transmitted infections (e.g. multiple sexual partners); 24. Known intolerance or allergy to any components of LevoCept, including intolerance or allergy to levonorgestrel, nickel, titanium, or silicone; 25. Currently participating or planning future participation in a research study of an investigational drug or device during the course of this investigational study. Subject must have waited at least 30 days from exiting their last study prior to informed consent in this study; 26. Subject has previously been enrolled in a VeraCept or LevoCept study (including the current study); 27. Known or suspected alcohol or drug abuse within 12 months prior to the screening visit; 28. Any general health, mental health or behavioral condition that, in the opinion of the investigator, could represent an increased risk for the subject or would render the subject less likely to provide the needed study information; 29. Study staff or a member of the immediate family of study staff.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LevoCept
Levonorgestrel-Releasing Intrauterine System

Locations

Country Name City State
United States Emory University School of Medicine Gynecology/Obstetrics Atlanta Georgia
United States University Of Colorado Department of Obstetrics & Gyncology Aurora Colorado
United States Essential Access Health-Berkeley Berkeley California
United States University of Cincinnati/Reproductive Medicine Research Cincinnati Ohio
United States Ohio State University Columbus Ohio
United States The Ohio State University Ob/Gyn Research Office Columbus Ohio
United States Soapstone Center for Clinical Research Decatur Georgia
United States University of Hawaii Honolulu Hawaii
United States Advances In Health Houston Texas
United States IU Health University Hospital Indianapolis Indiana
United States Rex Garn Mabey Jr., MD Las Vegas Nevada
United States Essential Access Health-Los Angeles Los Angeles California
United States Planned Parenthood of the St. Louis Region and Southwest Missouri Manchester Missouri
United States Planned Parenthood North Central States Minneapolis Minnesota
United States Columbia University Medical Center New York New York
United States Eastern Virginia Medical Norfolk Virginia
United States Tidewater Physicians for Women Norfolk Virginia
United States Clinical Research of Philadelphia, LLC Philadelphia Pennsylvania
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Magee-Womens Hospital, Center for Family Planning Research Pittsburgh Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States University of California Davis Health System Department of Obstetrics and Gynecology Sacramento California
United States University of Utah Healthcare Health Sciences Center Salt Lake City Utah
United States Women's Health Care Research San Diego California
United States WR-Medical Center for Clinical Research San Diego California
United States Seattle Women's: Health, Research, Gynecology Seattle Washington
United States Stanford University, Medical Center, Obstetrics and Gynecolocy Stanford California

Sponsors (2)

Lead Sponsor Collaborator
Sebela Women's Health Inc. PRA Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Contraceptive efficacy through 3 years of use as calculated by the Pearl Index through 3 years of use
Secondary Contraceptive efficacy at Years 4 and 5 as calculated by the Pearl Index Years 4 and 5 and cumulatively through Years 4 and 5
Secondary Pregnancy percentage Years 1 through 5
Secondary Ease of LevoCept placement Ease of LevoCept placement will be summarized for the Safety population as reported by the investigator (Very easy, Easy, Neither Easy nor Hard, Hard, Very Hard). Day 1 / LevoCept placement
Secondary LevoCept Placement success The number of subjects with either a successful or unsuccessful placement will be summarized Day 1 / LevoCept placement
Secondary Incidence of AEs and SAEs 5 years
Secondary Bleeding and spotting patterns Through year 1
Secondary Insertion pain assessed immediately after insertion Summarized for subjects with and without prior prophylactic pain medication as measured by an 11-Point Numeric Pain Rating Scale. The scale being 0 - 10 with 0 being no pain and 10 being the worse pain Day 1, immediately after insertion
Secondary Cumulative LevoCept continuation rates Continuation rates at Years 1, 2, 3, 4 and 5, Reasons for discontinuation will be summarized. Years 1 through 5
Secondary Cumulative LevoCept expulsion rates Years 1 through 5
Secondary Return to Fertility. Only for subjects requesting LevoCept removal to become pregnant. Subjects will be followed for either 1 year, until they decide to no longer try to conceive or they become pregnant, whichever comes first.
Secondary Release rate of LNG from the IUS and resulting pharmacokinetics of LNG (PK substudy) Years 1 through 5
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A